SKILLCELL
1.10.2020 18:25:11 CEST | Business Wire | Press release
EasyCOV, a virological saliva detection test for COVID19, has shown a sensitivity of 88% and a specificity 99% during a clinical trial performed at the testing center operated by the teaching hospital of Montpellier. The test relies on an optimized thermal protocol that provides the results in 40 minutes.
EasyCOV, developed by SkillCell in collaboration with the CNRS (French National Center for Scientific Research), is a saliva test that can be run in the field and that provides results in the form of a change of color in no more than 40 minutes. Performed by a healthcare professional, the test requires the collection of 200 microliters of saliva, approximately 4 drops, from under the patient’s tongue. The sample is heated successively in two tubes using the nomadic heating device EasyVID (developed and produced by TRONICO, sister company of SkillCell). A test turning bright yellow indicates that the virus has been detected while an orange test is negative.
A double-blind clinical trial has been conducted at the teaching hospital of Montpellier, France, in real life conditions at the testing center operated by the hospital. During this clinical trial, nasopharyngeal and saliva samples were collected simultaneously and analyzed via RT PCR. These two analyses were used as a basis to establish the infection status of the participants. This status was then compared to the results of EasyCOV test. This analysis showed a sensitivity of 87.5% and a specificity of 99.4% for 220 participants, including 40 positive patients with and without symptoms. EasyCOV test was performed using a thermal protocol giving results in 40 min.
EasyCOV demonstrates with this trial that it is high quality, faster, cost-efficient and not invasive test that can be performed in a large variety of locations without requiring heavy investments.
Alexandra Prieux, President of SkillCell commented « EasyCOV is a unique and necessary tool in the fight against COVID 19. It is a real satisfaction for the team that our test is able to bring a concrete answer to the sanitary and economic challenges that we face today. ».
The EasyCov programme is supported by the French Ministry of Armed Forces via the Direction Générale de l’Armement (Directorate General of Armaments - DGA) and the Agence de l’Innovation de Défense (Defense Innovation Agency - AID).
About SKILLCELL
SkillCell develops in-field diagnostic tests using its simplicity-centered approach: tests capable of being used by anybody, anywhere and at any time. Founded in Guadeloupe in 2017, the company has offices in France in Jarry (Guadeloupe), Paris and Montpellier. The SkillCell team brings together scientific experts and seasoned manufacturers to find solutions to medical and environmental diagnostic testing issues by providing relevant, high-quality information that allows users to make well-informed choices with full transparency. SkillCell is a subsidiary of ALCEN group. For more information: www.skillcell-alcen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005914/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom